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Background/Purpose:  
Once ANCA-associated vasculitis (AAV) remission was obtained, rituximab (RTX) 
superiority to azathioprine (AZA) to maintain remission was shown.1 In that study, at month 
28, only 5% of RTX recipients vs 29% taking AZA suffered major relapses. However, at 
present, neither ANCA-positivity and/or titers (status) nor peripheral blood CD19 B-cell–
detection are considered reliable AAV-relapse predictors. The MAINRITSAN2 trial 
(ClinicalTrials.gov, no. NCT01731561) was designed to evaluate RTX infusions individually 
tailored to ANCA status and/or circulating CD19 B-cell reappearance to maintain AAV 
remission. 
Methods:  
Patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in 
complete remission after induction therapy (glucocorticoids and cyclophosphamide, rituximab 
or methotrexate) were included in an open-label, multicenter, randomized–controlled trial to 
compare RTX regimens: given according to ANCA status and/or circulating CD19 B-cell 
reconstitution vs systematically infused (controls). The experimental arm received fixed, 500-
mg RTX infusions on day-0 postrandomization, then every 3 months until month 18, when 
CD19 lymphocytes exceeded 0/mm3 or ANCA status (reappearance)/titer (higher) differed 
from the previous determination. Controls received 500 mg of RTX on days 0 and 14 
postrandomization, then 6, 12 and 18 months after the first infusion. The primary endpoint 
was the number of relapses (new or reappearing symptom or worsening disease with 
BVAS>0) at month 28, as assessed by an independent Adjudication Committee blinded to 
treatment arms. 
Results: The 162 patients included [117 (72.2%) GPA and 45 (27.8%) MPA] were equally 
allocated to the experimental (n=81; 50%) and control (n=81; 50%) groups. Prerandomization 
induction therapy was cyclophosphamide for 100 (61.7%) patients, RTX for 61 (37.7%) or 
methotrexate for 1 (0.6%). Median RTX-infusion numbers were: 3 (interquartile range (IQR) 
2–4) for the experimental arm and 5 (IQR 5–5) for controls. Twenty-one (13%) patients 
suffered 22 relapses: 14 (17.3%) in 13 experimental arm patients and 8 (9.9%) in 8 controls 
(P=0.22). The relapse-free–survival rate was 83.8% (95% confidence interval [CI], 76.1–
92.3%) for the experimental arm and 86.4% (95% CI, 79.2–94.2) for controls (P=0.58). 
Twenty-six (32.1%) experimental arm patients experienced at least 1 severe adverse event vs 
31 (38.3%) controls (P=0.51). Four patients died, 1 of an infectious complication. No 
association between ANCA status and/or circulating CD19 B cells and relapses was observed. 
Conclusion: AAV-relapse rates for patients given individually tailored or systematic RTX-
infusion schedules did not differ significantly. However, ANCA and circulating CD19 B cells 
could be considered useful tools to decide to reinfuse because they achieved lower RTX total 
doses (i.e., 3 vs 5 infusions) to prevent relapses in the experimental arm. 
 
